Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.
2.

Concordance of deregulated mechanisms unveiled in underpowered experiments: PTBP1 knockdown case study.

Gardeux V, Arslan AD, Achour I, Ho TT, Beck WT, Lussier YA.

BMC Med Genomics. 2014;7 Suppl 1:S1. doi: 10.1186/1755-8794-7-S1-S1. Epub 2014 May 8.

3.

Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties.

He X, Arslan AD, Ho TT, Yuan C, Stampfer MR, Beck WT.

Oncogenesis. 2014 Jan 13;3:e84. doi: 10.1038/oncsis.2013.47.

4.

Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1.

Xie Y, Natarajan K, Bauer KS, Nakanishi T, Beck WT, Moreci RS, Jeyasuria P, Hussain A, Ross DD.

Biochim Biophys Acta. 2013 Dec;1829(12):1288-99. doi: 10.1016/j.bbagrm.2013.10.008. Epub 2013 Nov 2.

5.

A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing.

Arslan AD, He X, Wang M, Rumschlag-Booms E, Rong L, Beck WT.

J Biomol Screen. 2013 Feb;18(2):180-90. doi: 10.1177/1087057112459901. Epub 2012 Sep 12.

6.

Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.

Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L, Beck WT.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20778-83. doi: 10.1073/pnas.1019452108. Epub 2011 Dec 5.

7.

Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.

Das SG, Srinivasan B, Hermanson DL, Bleeker NP, Doshi JM, Tang R, Beck WT, Xing C.

J Med Chem. 2011 Aug 25;54(16):5937-48. doi: 10.1021/jm200764t. Epub 2011 Aug 3.

PMID:
21780800
8.

Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.

Natarajan K, Xie Y, Nakanishi T, Beck WT, Bauer KS, Ross DD.

Biochim Biophys Acta. 2011 Jul;1809(7):295-305. doi: 10.1016/j.bbagrm.2011.06.004. Epub 2011 Jun 28.

9.

Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.

Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WT.

Mol Pharmacol. 2011 Apr;79(4):735-41. doi: 10.1124/mol.110.069633. Epub 2011 Jan 20.

10.

Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.

He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, Beck WT.

Oncogene. 2011 Jan 20;30(3):356-65. doi: 10.1038/onc.2010.426. Epub 2010 Sep 20.

11.

Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, Safa AR, Beck WT, Erickson LC.

J Pharmacol Exp Ther. 2009 Aug;330(2):423-9. doi: 10.1124/jpet.109.153551. Epub 2009 May 7.

12.

MicroRNA-mediated regulation of Ubc9 expression in cancer cells.

Wu F, Zhu S, Ding Y, Beck WT, Mo YY.

Clin Cancer Res. 2009 Mar 1;15(5):1550-7. doi: 10.1158/1078-0432.CCR-08-0820. Epub 2009 Feb 17.

13.

Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.

Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC.

J Pharmacol Exp Ther. 2008 Jan;324(1):95-102. Epub 2007 Oct 18.

PMID:
17947497
14.

Gam1-associated alterations of drug responsiveness through activation of apoptosis.

Wu F, Chiocca S, Beck WT, Mo YY.

Mol Cancer Ther. 2007 Jun;6(6):1823-30.

15.

Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.

He X, Pool M, Darcy KM, Lim SB, Auersperg N, Coon JS, Beck WT.

Oncogene. 2007 Jul 26;26(34):4961-8. Epub 2007 Feb 19.

16.

Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.

Mirski SE, Sparks KE, Friedrich B, Köhler M, Mo YY, Beck WT, Cole SP.

Exp Cell Res. 2007 Feb 1;313(3):627-37. Epub 2006 Nov 10.

PMID:
17182034
17.

Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites.

Kamalakaran S, Radhakrishnan SK, Beck WT.

J Biol Chem. 2005 Jun 3;280(22):21491-7. Epub 2005 Mar 24.

18.

A role for Ubc9 in tumorigenesis.

Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT.

Oncogene. 2005 Apr 14;24(16):2677-83.

PMID:
15735760
19.

Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

Ee PL, He X, Ross DD, Beck WT.

Mol Cancer Ther. 2004 Dec;3(12):1577-83.

21.
22.

Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.

Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT.

Cancer Res. 2004 Feb 15;64(4):1247-51.

23.

Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.

Rallabhandi P, Hashimoto K, Mo YY, Beck WT, Moitra PK, D'Arpa P.

J Biol Chem. 2002 Oct 18;277(42):40020-6. Epub 2002 Jul 30.

24.

Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis.

Tavormina PA, Côme MG, Hudson JR, Mo YY, Beck WT, Gorbsky GJ.

J Cell Biol. 2002 Jul 8;158(1):23-9. Epub 2002 Jul 8.

25.

Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.

Mo YY, Yu Y, Shen Z, Beck WT.

J Biol Chem. 2002 Jan 25;277(4):2958-64. Epub 2001 Nov 14.

26.

Cytotoxic signalling by inhibitors of DNA topoisomerase II.

Beck WT, Mo YY, Bhat UG.

Biochem Soc Trans. 2001 Nov;29(Pt 6):702-3. Review.

PMID:
11709058
27.

Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexes.

Cai L, Lim K, Ren S, Cadena RS, Beck WT.

J Med Chem. 2001 Aug 30;44(18):2959-65.

PMID:
11520204
28.

Tumor cell resistance to DNA topoisomerase II inhibitors: new developments.

Beck WT, Morgan SE, Mo YY, Bhat UG.

Drug Resist Updat. 1999 Dec;2(6):382-389.

PMID:
11498354
30.

Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.

Morgan SE, Kim R, Wang PC, Bhat UG, Kusumoto H, Lu T, Beck WT.

Oncogene. 2000 Oct 12;19(43):5010-9.

31.

A novel nuclear localization signal in human DNA topoisomerase I.

Mo YY, Wang C, Beck WT.

J Biol Chem. 2000 Dec 29;275(52):41107-13.

32.

Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.

Mo YY, Wang P, Beck WT.

Exp Cell Res. 2000 May 1;256(2):480-90.

PMID:
10772820
36.

Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.

Bhat UG, Raychaudhuri P, Beck WT.

Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7859-64.

38.

DNA damage signals induction of fas ligand in tumor cells.

Mo YY, Beck WT.

Mol Pharmacol. 1999 Feb;55(2):216-22.

PMID:
9927611
40.
41.

Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.

Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH.

Biochem Pharmacol. 1998 Sep 15;56(6):719-27.

PMID:
9751076
42.

Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents.

Dolan ME, Frydman B, Thompson CB, Diamond AM, Garbiras BJ, Safa AR, Beck WT, Marton LJ.

Anticancer Drugs. 1998 Jun;9(5):437-48.

PMID:
9660542
44.
45.

Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.

Scheltema JM, Romijn JC, van Steenbrugge GJ, Beck WT, Schröder FH, Mickisch GH.

J Cancer Res Clin Oncol. 1997;123(10):546-54.

PMID:
9393588
46.

Novel mechanisms of resistance to inhibitors of DNA topoisomerases.

Beck WT, Khélifa T, Kusumoto H, Mo YY, Rodgers Q, Wolverton JS, Wang Q.

Adv Enzyme Regul. 1997;37:17-26. No abstract available.

PMID:
9381970
47.

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck WT, Herrmann DB, Grunicke H.

Br J Cancer. 1997;76(7):862-9.

48.
49.

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R.

Cancer Res. 1996 Jul 1;56(13):3010-20. Review.

50.

Antitopoisomerase drug action and resistance.

Nitiss JL, Beck WT.

Eur J Cancer. 1996 Jun;32A(6):958-66. Review. No abstract available.

PMID:
8763336

Supplemental Content

Support Center